Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. 2005

M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
Division of Supportive Care, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.

BACKGROUND Invasive fungal infections (IFI) in immunocompromised patients are associated with significant morbidity and mortality, despite appropriate antifungal treatment and recovery from neutropenia. The outcome of these infections depends significantly on the overall state of immunosuppression, including mainly the phagocytic system (neutrophils and macrophages). Interferon-gamma (IFN-gamma), granulocyte-colony--stimulating factor (G-CSF) and granulocyte-macrophage-colony--stimulating factor (GM-CSF) are cytokines that enhance the activity of neutrophils and macrophages. METHODS The authors reported 4 patients with leukemia and refractory invasive candidiasis or trichosporonosis despite 1-13 months of appropriate antifungal treatment. RESULTS Cytokines were administered for 1.5-5 months without significant toxicity. For each patient, initiation of interferon-gamma plus a colony-stimulating factor resulted in a clinical response. The contribution of cytokines to control the fungal infection in these 4 patients was suggested by the strong inflammatory reaction observed in the 2 patients who had an immediate response (within 7 days of initiation of cytokine therapy) and by the good outcome in the 2 other patients in whom antifungal agents were discontinued at the start of cytokine therapy. CONCLUSIONS These data suggested a potential role for immunomodulation in patients with leukemia with refractory invasive fungal infections.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid

Related Publications

M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
August 2004, The Pediatric infectious disease journal,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 1999, Reviews of physiology, biochemistry and pharmacology,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 2006, Neonatal network : NN,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
April 1999, The Journal of infectious diseases,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
August 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
August 2008, Infection,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 1993, FEMS immunology and medical microbiology,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 1995, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
M Cecilia Dignani, and John H Rex, and Ka-Wah Chan, and Gordon Dow, and Margarida deMagalhaes-Silverman, and AnneMarie Maddox, and Thomas Walsh, and Elias Anaissie
January 1989, Acta haematologica,
Copied contents to your clipboard!